Antiplatelet Therapy in Cardiovascular Disease

349 Pages·2016·2.84 MB·English

by  Ron Waksman, Paul A. Gurbel and Michael A. Gaglia Jr.

17mm 3mm (left) +152mm + 3mm (right) 20mm 3mm (left) +152mm + 3mm (right) 17mm
Waksman
Gurbel
Antiplatelet Gaglia
Antiplatelet
Therapyin Cardiovascular Disease
Edited by
Ron Waksman, MD, FAC, Asociate Chief of Cardiology, Therapy
Director of Cardiovascular Research and Advanced
Education, MedStar Heart Institute at MedStar
Washington Hospital Center, Washington, DC, USA
in Cardiovascular Disease
Paul A. Gurbel, MD, FACC, FAHA, Director, Sinai Center
for Thrombosis Research, Sinai Hospital of Baltimore;
Professor of Medicine, Johns Hopkins University School
of Medicine, Baltimore, MD, USA
Michael A. Gaglia, Jr., MD, MSc, Assistant Professor of
Medicine, Division of Cardiovascular Medicine, University
of Southern California Keck School of Medicine,
Los Angeles, CA, USA
Edited by a team of the world’s leading interventional cardiologists and educators, this new
book is created with an eye on giving the reader a solid, practical, and clinically focused
understanding of this important class of drugs, from basic science to a clear-headed
discussion of complex topics such as combination therapies, drug–drug interactions, and
resistance to antiplatelet agents.
This important new book:
• Begins with a concise but thorough discussion of platelet biology and pathophysiology so
that readers understand how antiplatelet agents work and why they produce such a varied
range of complications, from minor gastrointestinal upset to potentially life-threatening
conditions such as neutropenia, a critical shortage of white blood cells.
• Thoroughly covers platelet function testing, including new, novel techniques.
• Clarifies current best practices regarding the use of antiplatelet agents in both chronic and
acute cardiovascular disease.
• Reviews all types of antiplatelet agents – from aspirin to recently approved drugs –
including indications, clinical outcomes, and side effects/complications.
Written by an international ‘who’s who’ of experts in the field, Antiplatelet Therapy in
Cardiovascular Disease also includes an entire section covering the use of antiplatelet drugs
in PCIs, including percutaneous valve repair, which makes this text particularly essential to
interventional cardiologists.
ISBN 978-1-118-27575-7 Edited by
Ron Waksman, Paul A. Gurbel and Michael A. Gaglia Jr.
9 781118 275757
www.wiley.com/go/cardiology
PPC - Trim Size 152x229mm
Antiplatelet Therapy in Cardiovascular Disease
17mm 2mm (bottom) +229mm + 2mm (top) 17mm
Antiplatelet Therapy in
Cardiovascular Disease
Antiplatelet
Therapy in
Cardiovascular
Disease
EDiTED by
Ron Waksman, MD, FACC
Associate Chief of Cardiology
Director of Cardiovascular Research and Advanced Education
MedStar Heart institute at MedStar Washington Hospital Center
Washington, DC, USA
Paul A. Gurbel, MD, FACC, FAHA
Director, Sinai Center for Thrombosis Research
Associate Chief for Research
Department of Medicine
Sinai Hospital of baltimore;
Professor of Medicine
Johns Hopkins University School of Medicine
baltimore, MD;
Adjunct Professor of Medicine
Duke University School of Medicine
Durham, NC, USA
Michael A. Gaglia, Jr., MD, MSc
Assistant Professor of Medicine
Division of Cardiovascular Medicine
University of Southern California Keck School of Medicine
Los Angeles, CA, USA
This edition first published 2014 © 2014 by John Wiley & Sons, Ltd
Registered office
John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial offices
9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
111 River Street, Hoboken, NJ 07030-5774, USA
For details of our global editorial offices, for customer services and for information about how
to apply for permission to reuse the copyright material in this book please see our website at
www.wiley.com/wiley-blackwell
The right of the author to be identified as the author of this work has been asserted in accordance
with the UK Copyright, Designs and Patents Act 1988.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system,
or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or
otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the
prior permission of the publisher.
Designations used by companies to distinguish their products are often claimed as trademarks.
All brand names and product names used in this book are trade names, service marks, trademarks
or registered trademarks of their respective owners. The publisher is not associated with any
product or vendor mentioned in this book. it is sold on the understanding that the publisher is
not engaged in rendering professional services. if professional advice or other expert assistance
is required, the services of a competent professional should be sought.
The contents of this work are intended to further general scientific research, understanding,
and discussion only and are not intended and should not be relied upon as recommending or
promoting a specific method, diagnosis, or treatment by health science practitioners for any
particular patient. The publisher and the author make no representations or warranties with
respect to the accuracy or completeness of the contents of this work and specifically disclaim
all warranties, including without limitation any implied warranties of fitness for a particular
purpose. in view of ongoing research, equipment modifications, changes in governmental
regulations, and the constant flow of information relating to the use of medicines, equipment, and
devices, the reader is urged to review and evaluate the information provided in the package insert
or instructions for each medicine, equipment, or device for, among other things, any changes in
the instructions or indication of usage and for added warnings and precautions. Readers should
consult with a specialist where appropriate. The fact that an organization or Website is referred
to in this work as a citation and/or a potential source of further information does not mean that
the author or the publisher endorses the information the organization or Website may provide
or recommendations it may make. Further, readers should be aware that internet Websites listed
in this work may have changed or disappeared between when this work was written and when it
is read. No warranty may be created or extended by any promotional statements for this work.
Neither the publisher nor the author shall be liable for any damages arising herefrom.
Library of Congress Cataloging-in-Publication Data
is available for title 9781118275757
A catalogue record for this book is available from the british Library.
Wiley also publishes its books in a variety of electronic formats. Some content that appears in print
may not be available in electronic books.
Cover image: iStock Photo #10819113 © raulov
Set in 9.25/11.5pt Minion by SPi Publisher Services, Pondicherry, india
1 2014
Contents
List of Contributors, viii
Foreword, xix
Preface, xxi
Section I: Platelet biology and Pathophysiology
1 Platelet Pathophysiology and its Role in Thrombosis, 3
Paul A. Gurbel and Udaya S. Tantry
2 Platelet Receptors and Drug Targets: COX-1, 8
Thomas Hohlfeld and Karsten Schrör
3 Platelet Receptors and Drug Targets: P2y12, 14
Marco Cattaneo
4 Platelet Receptors and Drug Targets: GP iib/iiia, 21
Eliano Pio Navarese and Jacek Kubica
5 P latelet Receptors and Drug Targets: PAR1, Collagen, vWF,
Thromboxane, and Other Novel Targets, 29
Ping Zhang, Lidija Covic, and Athan Kuliopulos
6 Role of inflammation and Hypercoagulability in Thrombosis, 45
Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry
Section II: Platelet Function tests
7 Light Transmission Aggregometry, 53
Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry
8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58
Marc Laine, Franck Paganelli, and Laurent Bonello
9 VerifyNow P2y12 and Plateletworks Assays, 65
Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg
10 Multiplate Analyzer, 82
Martin orban and Dirk Sibbing
11 S hear Stress-based Platelet Function Tests, 92
Nicoline J. Breet and Jurriën M. ten Berg
v
vi Contents
12 T hrombelastography and Other Novel Techniques, 102
Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken,
Marvin J. Slepian, and Paul A. Gurbel
Section III: Antiplatelet Pharmacology
13 Aspirin, 111
Karsten Schrör and Thomas Hohlfeld
14 Cilostazol, 117
Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park
15 Abciximab, 125
J. Emilio Exaire and Jorge F. Saucedo
16 Tirofiban, 131
Marco Valgimigli, Arnoud W.J. van’t Hof, and Christian Hamm
17 Eptifibatide, 142
Nevin C. Baker and Ron Waksman
18 Ticlopidine, 150
Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano,
and Dominick J. Angiolillo
19 Clopidogrel, 160
Andrzej Budaj
20 Prasugrel, 166
Christoph Varenhorst, Anna oskarsson, and Stefan James
21 Elinogrel, 173
Matthew J. Chung and Sunil V. Rao
22 Cangrelor, 180
Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano,
and Dominick J. Angiolillo
23 Ticagrelor, 193
Anna oskarsson, Christoph Varenhorst, and Stefan James
24 T hrombin Receptor Antagonists, 198
Flávio de Souza Brito and Pierluigi Tricoci
Section IV: Percutaneous Coronary Intervention
and Antiplatelet therapy
25 D ual Antiplatelet Therapy Prior to Percutaneous Coronary
intervention, 209
Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi,
and Germano di Sciascio
26 D uration of Dual Antiplatelet Therapy after Drug-Eluting
Stent implantation, 220
Joshua P. Loh and Ron Waksman
Contents vi
27 Antiplatelet Therapy for Patients with Acute Coronary
Syndromes, 29
Michael A. Gaglia, Jr. and Ray V. Matthews
28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237
Ana Laynez and Ron Waksman
29 Antiplatelet Therapy for Patients with Peripheral
Arterial Disease, 245
Aung Myat, Yousif Ahmad, and Simon R. Redwood
30 leding Risk b and Outcomes of Patients Undergoing Percutaneous
Coronary intervention Treated with Antiplatelets, 253
Sa’ar Minha and Ron Waksman
31 leding b Definitions, 259
Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran
Section V: Antiplatelet Responsiveness
32 Personalizing Antiplatelet Therapy, 269
Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry
3 Aspirin Resistance, 27
Muthiah Vaduganathan and Eli I. Lev
34 Clopidogrel Resistance, 285
Udaya S. Tantry, Kevin P. Bliden, Talha Meran,
and Paul A. Gurbel
35 Genetics of Clopidogrel Por Response, 293
Piere Fontana and Jean-Luc Reny
3 6 P roton Pump inhibitors and Clopidogrel, 300
Michael A. Gaglia, Jr
3 7 O ther Drug interactions with Clopidogrel, 306
Eric R. Bates
index, 314
List of Contributors
Yousif Ahmad, BMedSci, BMBS, MRCP
Cardiology SpR and Honorary Research Fellow
National Heart and Lung institute
imperial College London
London;
University of birmingham Centre for Cardiovascular Sciences
City Hospital
birmingham, UK
Dominick J. Angiolillo, MD, PhD
Associate Professor of Medicine
Director, Cardiovascular Research
University of Florida College of Medicine
Jacksonville, FL, USA
Nachiket Apte, MBBS
Resident
Sinai Center for Thrombosis Research
Sinai Hospital of baltimore;
Johns Hopkins University School of Medicine
baltimore, MD, USA
Deborah E. Aronson, PhD
Medical Publication Editor
The Zena and Michael A. Wiener Cardiovascular institute
The icahn School of Medicine at Mount Sinai
New york, Ny, USA
Nevin C. Baker, DO
Fellow, interventional Cardiology
MedStar Washington Hospital Center
Washington, DC, USA
Sameer Bansilal, MD, MS
Assistant Professor
The Zena and Michael A. Wiener Cardiovascular institute
The icahn School of Medicine at Mount Sinai
New york, Ny, USA
viii
www.cambodiamed.blogspot.com